Biological Psychiatry of Cancer and Cancer Treatment

Mapping Intimacies ◽

10.1093/med/9780198759911.001.0001 ◽

2016 ◽

Cited By ~ 1

Author(s):

Andrew Hodgkiss

Keyword(s):

Psychiatric Disorders ◽

Cancer Survival ◽

Biological Psychiatry ◽

Cancer Treatments ◽

Glucocorticoid Treatment ◽

Brain Irradiation ◽

Quality Cancer Care ◽

Molecularly Targeted Agents ◽

Onconeuronal Antibodies

As long-term cancer survival becomes a widely shared experience, the quality of life of people living with and beyond a cancer diagnosis is increasingly important. Optimizing the prevention and treatment of any psychiatric consequences of certain tumours and treatments is now central to high-quality cancer care. This book—a rather original addition to the oncology and psycho-oncology literature—aims to equip oncology clinicians with the knowledge to more expertly prevent, detect, and manage the ‘organic’ psychiatric disorders experienced by people with cancer. It will also serve as a valuable introduction to contemporary oncology for psychiatrists.The psychiatry of cancer is a distinct subject within the wider field of psycho-oncology. Psychiatric disorders arising through direct biological mechanisms from particular tumours or cancer treatments is a narrower topic still, but one in which oncologists are required to have expertise. This book considers in detail the psychiatric aspects of pro-inflammatory cytokines, endocrine paraneoplastic syndromes, onconeuronal antibodies, brain irradiation, hormone deprivation, glucocorticoid treatment, conventional chemotherapies, and molecularly targeted agents.

Download Full-text

[18F]Fluoride PET Indicates Reduced Bone Formation in Severe Glucocorticoid-induced Osteoporosis

Nuklearmedizin ◽

10.1055/s-0038-1629797 ◽

1998 ◽

Vol 37 (02) ◽

pp. 76-79 ◽

Cited By ~ 8

Author(s):

T. D. Kirchhoff ◽

W. Burchert ◽

J. v. d. Hoff ◽

H. Zeidler ◽

H. Hundeshagen ◽

...

Keyword(s):

Bone Formation ◽

Multiple Organ ◽

High Dose ◽

Multiple Fractures ◽

Glucocorticoid Treatment ◽

Organ Manifestations ◽

Diagnostic Benefit ◽

Sharp Syndrome ◽

18F Fluoride

SummaryA 61-year-old female patient presenting with mixed connective tissue disease (Sharp syndrome), underwent a long-term high dose glucocorticoid treatment because of multiple organ manifestations. Under steroid therapy she developed severe osteoporosis resulting in multiple fractures. A dynamic [18F]fluoride PET study in this patient revealed reduced fluoride influx in non-fractured vertebrae. This finding corresponds to pathogenetic concepts which propose an inhibition of bone formation as major cause of glucocorticoid-induced osteoporosis. In the light of the presented case it seems to be promising to evaluate the diagnostic benefit of [18F]fluoride PET in osteoporosis.

Download Full-text

Metabolic abnormalities in patients with chronic psychiatric disorders receiving long-term psychopharmacological treatment

Pharmacopsychiatry ◽

10.1055/s-2005-918809 ◽

2005 ◽

Vol 38 (05) ◽

Author(s):

B Reisinger ◽

E Mueller ◽

B Kropp-Hartmann ◽

D Wölflick ◽

C Zimmerer ◽

...

Keyword(s):

Psychiatric Disorders ◽

Metabolic Abnormalities ◽

Psychopharmacological Treatment

Download Full-text

Management of hyperglycaemia risk in patients on medium or long-term glucocorticoid treatment: a retrospective pilot study

Endocrine Abstracts ◽

10.1530/endoabs.63.p887 ◽

2019 ◽

Author(s):

Helen Greenfield ◽

Mohit Kumar

Keyword(s):

Pilot Study ◽

Glucocorticoid Treatment

Download Full-text

Psychiatric comorbid disorders of cognition: a machine learning approach using 1175 UK Biobank participants

Evidence-Based Mental Health ◽

10.1136/ebmental-2020-300147 ◽

2020 ◽

Vol 23 (4) ◽

pp. 140-145

Author(s):

Chenlu Li ◽

Delia A Gheorghe ◽

John E Gallacher ◽

Sarah Bauermeister

Keyword(s):

Machine Learning ◽

Cognitive Decline ◽

Psychiatric Disorders ◽

Characteristic Curve ◽

Area Under The Curve ◽

Imaging Study ◽

Cognitive Change ◽

Poor Mental Health ◽

Uk Biobank

BackgroundConceptualising comorbidity is complex and the term is used variously. Here, it is the coexistence of two or more diagnoses which might be defined as ‘chronic’ and, although they may be pathologically related, they may also act independently. Of interest here is the comorbidity of common psychiatric disorders and impaired cognition.ObjectivesTo examine whether anxiety and/or depression are/is important longitudinal predictors of cognitive change.MethodsUK Biobank participants used at three time points (n=502 664): baseline, first follow-up (n=20 257) and first imaging study (n=40 199). Participants with no missing data were 1175 participants aged 40–70 years, 41% women. Machine learning was applied and the main outcome measure of reaction time intraindividual variability (cognition) was used.FindingsUsing the area under the receiver operating characteristic curve, the anxiety model achieves the best performance with an area under the curve (AUC) of 0.68, followed by the depression model with an AUC of 0.63. The cardiovascular and diabetes model, and the covariates model have weaker performance in predicting cognition, with an AUC of 0.60 and 0.56, respectively.ConclusionsOutcomes suggest that psychiatric disorders are more important comorbidities of long-term cognitive change than diabetes and cardiovascular disease, and demographic factors. Findings suggest that psychiatric disorders (anxiety and depression) may have a deleterious effect on long-term cognition and should be considered as an important comorbid disorder of cognitive decline.Clinical implicationsImportant predictive effects of poor mental health on longitudinal cognitive decline should be considered in secondary and also primary care.

Download Full-text

Cancer Care and Survivorship Planning: Promises and Challenges

Journal of Oncology Practice ◽

10.1200/jop.0934407 ◽

2009 ◽

Vol 5 (3) ◽

pp. 116-118 ◽

Cited By ~ 7

Author(s):

Len Lichtenfeld

Keyword(s):

Cancer Care ◽

Long Term Effects ◽

Cancer Treatments ◽

The Impact

Although we have made some progress in understanding long-term effects of some cancer treatments, there is still much more to learn about the impact of our treatments on our patients.

Download Full-text